Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
When an important concept puts a scientific paper under the spotlight, behind the scenes there is usually a long story of mystery solving, as Philip Petersen explains.
In 1664, Robert Boyle wrote: “So much admirable workmanship, as God hath displayed in the Universe, was never meant for eyes that willfully close themselves.” It is scientists' duty to make a convincing effort to ensure that this admirable workmanship is there for all to see.
Verena Schulze Greiving and Kornelia Konrad describe a toolbox that they developed to support researchers in exploring the societal implications and prerequisites of their work.
Strategic timing can be key for nano-drug-delivery ventures to get financing. Timely publications engage potential partners; early broad, blocking, relevant patents demonstrate the potential to appropriate value; and venture formation closer to clinical viability better aligns its timeline with that of venture capitalists.
Ilse Marschalek and Margit Hofer reflect on the outcome of their international NanOpinion project, focusing on raising public awareness about nanotechnology.
